A first-in-human phase Ia dose escalation study of GDC-0077, a p110a-selective and mutant-degrading PI3K inhibitor, in patients with PIK3CA-mutant solid tumors

被引：9

作者：

Juric, Dejan ^{[1
]}

Kalinsky, Kevin ^{[2
]}

Oliveira, Mafalda ^{[3
,4
]}

Cervantes, Andres ^{[5
]}

Bedard, Philippe ^{[6
,7
]}

Krop, Ian ^{[8
]}

Hamilton, Erika ^{[9
]}

Schmid, Peter ^{[10
]}

Varga, Andrea ^{[11
]}

Turner, Nick ^{[12
]}

Italiano, Antoine ^{[13
]}

Saura, Cristina ^{[3
,4
]}

Gambardella, Valentina ^{[5
]}

Veitch, Zachary ^{[6
,7
]}

Dickmann, Leslie ^{[14
]}

Kotani, Naoki ^{[14
]}

Fredrickson, Jill ^{[14
]}

Kapp, Amy ^{[14
]}

Hutchinson, Katie ^{[14
]}

Royer-Joo, Stephanie ^{[14
]}

Vaze, Anjali ^{[14
]}

Schutzman, Jennifer ^{[14
]}

Jhaveri, Komal ^{[15
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Columbia Univ, Irving Med Ctr, New York, NY USA

[3] Vall dHebron Univ Hosp, Barcelona, Spain

[4] Vall dHebron Inst Oncol, Barcelona, Spain

[5] Univ Valencia, Valencia, Spain

[6] Princess Margaret Canc Ctr, Toronto, ON, Canada

[7] Univ Toronto, Toronto, ON, Canada

[8] Dana Farber Canc Inst, Boston, MA 02115 USA

[9] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[10] Queen Mary Univ London, Barts Canc Inst, London, England

[11] Gustave Roussy Canc Campus, Villejuif, France

[12] Inst Canc Res, London, England

[13] Inst Bergonie, Bordeaux, France

[14] Genentech Inc, San Francisco, CA 94080 USA

[15] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-OT1-08-04

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OT1-08-04

引用

页数：3

共 50 条

[41] First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer
Saura, Cristina
Sanz, Lucia
Kim, Janice
Jhaveri, Komal L.
Guerrero, Angel
Ortega, Pablo Tolosa
Schott, Anne F.
Curigliano, Giuseppe
Perez, Cesar Augusto
Nanda, Rita
Hamilton, Erika P.
Henry, Jason Timothy
Wisinski, Kari Braun
Sammons, Sarah L.
Segar, Jennifer Margaret
Aix, Santiago Ponce
Sirven, Milana Bergamino
Spira, Alexander I.
Schram, Alison M.
Varkaris, Andreas
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[42] A first-in-human, phase 1a, dose-escalation study of BGB-10188, a phosphatidylinositol 3-kinase delta (PI3K δ) inhibitor, plus tislelizumab (anti-PD-1) in patients with solid tumors
Cosman, Rasha
Ahern, Elizabeth
Li, Jie
Gan, Hui K.
Chen, Yu
Gao, Bo
Wang, Yongsheng
Mu, Xiyan
Cheng, Huan
Qian, Yanrong
Zhang, Heather
Cao, Ke
[J]. CANCER RESEARCH, 2024, 84 (07)
[43] A first-in-human, phase I study to evaluate the dual PI3K/mTOR inhibitor GDC-0980 administered QD in patients with advanced solid tumors or non-Hodgkin's lymphoma
Dolly, S.
Wagner, A. J.
Bendell, J. C.
Yan, Y.
Ware, J. A.
Mazina, K. E.
Holden, S. N.
Derynck, M. K.
De Bono, J. S.
Burris, H. A., III
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[44] SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumors.
Baselga, Jose
Cortes, Javier
De Laurentiis, Michele
Dieras, Veronique
Harbeck, Nadia
Hsu, Jerry Y.
Ng, Vivian
Schimmoller, Frauke
Wilson, Timothy R.
Im, Young-Hyuck
Jacot, William
Krop, Ian E.
Verma, Sunil
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[45] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Geoffrey I. Shapiro
Patricia LoRusso
Eunice Kwak
Susan Pandya
Charles M. Rudin
Carla Kurkjian
James M. Cleary
Mary Jo Pilat
Suzanne Jones
Alex de Crespigny
Jill Fredrickson
Luna Musib
Yibing Yan
Matthew Wongchenko
Hsin-Ju Hsieh
Mary R. Gates
Iris T. Chan
Johanna Bendell
[J]. Investigational New Drugs, 2020, 38 : 419 - 432
[46] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
Shapiro, Geoffrey, I
LoRusso, Patricia
Kwak, Eunice
Pandya, Susan
Rudin, Charles M.
Kurkjian, Carla
Cleary, James M.
Pilat, Mary Jo
Jones, Suzanne
de Crespigny, Alex
Fredrickson, Jill
Musib, Luna
Yan, Yibing
Wongchenko, Matthew
Hsieh, Hsin-Ju
Gates, Mary R.
Chan, Iris T.
Bendell, Johanna
[J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 419 - 432
[47] A phase 1 first-in-human (FIH) dose-escalation (DE) study of the oral dual PI3K/mTOR inhibitor PQR309 in patients (pts) with advanced solid tumors: Final DE results.
Kristeleit, Rebecca Sophie
Brown, Nicholas F.
Hess, Dagmar
Joerger, Markus
Von Moos, Roger
Rodon, Jordi
Hierro, Cinta
Childs, Alexa
Stathis, Anastasios
Dimitrijevic, Sasa
Stumm, Michael
Herrmann, Richard
Sessa, Cristiana
Bize, Vincent
Hess, Viviane
Wicki, Andreas
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[48] A FIRST-IN-HUMAN PHASE I STUDY TO EVALUATE THE DUAL PI3K/MTOR INHIBITOR GDC-0980 ADMINISTERED QD IN PATIENTS WITH ADVANCED SOLID TUMORS OR NON-HODGKIN S LYMPHOMA (NHL)
Bendell, J. C.
Wagner, A. J.
Dolly, S.
Morgan, J. A.
Papadatos-Pastos, D.
Ware, J.
Mazina, K. E.
Lauchle, J.
Burris, H.
De Bono, J.
[J]. ANNALS OF ONCOLOGY, 2010, 21 : 162 - 163
[49] SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with oestrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA-mutant tumours
Baselga, J.
Cortes Castan, J.
De Laurentiis, M.
Dieras, V.
Harbeck, N.
Hsu, J.
Jin, H.
Schimmoller, F.
Wilson, T. R.
Im, Y-H.
Jacot, W.
Krop, I. E.
Verma, S.
[J]. ANNALS OF ONCOLOGY, 2016, 27
[50] Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P) plus fulvestrant (F) in patients with PIK3CA-mutant/hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer (HR+/HER2-LA/MBC)
Turner, Nicolas
Jhaveri, Komal
Kalinsky, Kevin
Loibl, Sibylle
Loi, Sherene
Im, Seock-Ah
Saura, Cristina
Schmid, Peter
Schutzman, Jennifer L.
Stout, Thomas J.
Lei, Guiyuan
Hutchinson, Katherine E.
Thanopoulou, Eirini
Juric, Dejan
[J]. CANCER RESEARCH, 2021, 81 (04)

← 1 2 3 4 5 →